New hope for GVHD patients: experimental drug Q702 enters human testing

NCT ID NCT07138196

Recruiting now Disease control Sponsor: Qurient Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 22 times

Summary

This early-stage trial tests an experimental drug called Q702 in 18 adults with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body and whether it helps control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinica Universidad de Navarra
RECRUITING

Pamplona, Spain
Hospital Clinic de Barcelona
RECRUITING

Barcelona, Spain
Hospital General Universitario Gregorio Maranon
RECRUITING

Madrid, Spain
Hospital Universitario Marques de Valdecilla
RECRUITING

Santander, Spain
Hospital Universitario Puerta de Hierro Majadahonda
RECRUITING

Majadahonda, Spain
Hospital Universitario Virgen de la Arrixaca
RECRUITING

Murcia, Spain
Hospital Universitario Virgen del Rocio
RECRUITING

Seville, Spain
Instituto de Investigacion Sanitaria
RECRUITING

Valencia, Spain

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VERSUS HOST DISEASE